Pilocytic Astrocytoma: Understanding Your Pathology Report

by Jason Wasserman MD PhD FRCPC
April 24, 2026

Pilocytic astrocytoma is a type of brain tumor that develops from astrocytes, star-shaped support cells found throughout the brain and spinal cord. It is considered a low-grade tumor, meaning the cells grow slowly and typically do not invade the surrounding brain tissue the way more aggressive tumors do. Pilocytic astrocytomas are also described as well-circumscribed, meaning the tumor has a clear border with the normal brain around it, unlike a group of more aggressive tumors called diffuse gliomas, which blend into the normal brain and cannot be completely separated from it. This clear border is an important reason why pilocytic astrocytoma can often be cured by surgery alone. Pilocytic astrocytoma most often affects children, teenagers, and young adults, and is one of the most common brain tumors diagnosed in these age groups.

These tumors arise most commonly in the cerebellum (the part of the brain at the back of the head that controls balance and coordination), but they can also develop in the optic nerves and optic pathway, brainstem, hypothalamus, spinal cord, or cerebral hemispheres. Where the tumor grows has a major effect on symptoms, how easily it can be removed, and long-term outcome.

This article will help you understand the findings in your pathology report — what each term means and why it matters for your care or the care of your child.

What are the symptoms of pilocytic astrocytoma?

The symptoms of pilocytic astrocytoma depend on where the tumor is growing and how much it presses on nearby structures. Because these tumors grow slowly, symptoms often develop gradually over weeks or months rather than suddenly.

Tumors in the cerebellum can cause headache, nausea, and vomiting, often worse in the morning. These symptoms are caused by hydrocephalus — a build-up of fluid and pressure inside the skull that occurs when the tumor blocks the normal flow of cerebrospinal fluid (the clear fluid that surrounds the brain and spinal cord). Cerebellar tumors can also cause problems with balance, coordination, and walking.

Tumors along the optic pathway (the nerves that carry visual information from the eyes to the brain) can cause changes in vision, vision loss, or abnormal eye movements. In young children, these tumors may be detected when a parent or doctor notices that the child’s eyes do not track normally or that one eye appears to turn.

Tumors near the hypothalamus (a small region at the base of the brain that controls hormones, appetite, and sleep) can cause changes in growth, weight, thirst, puberty, or behavior. Spinal cord tumors can cause back pain, weakness, numbness, or bladder and bowel problems.

Some pilocytic astrocytomas cause seizures. Others are discovered incidentally during brain imaging for another reason, such as a head injury.

What causes pilocytic astrocytoma?

Pilocytic astrocytoma is caused by genetic changes in astrocytes that switch on a cellular signaling pathway called MAPK (sometimes written as MAPK/ERK). The MAPK pathway normally helps control how cells grow and divide. When it is switched on inappropriately, astrocytes begin to multiply more than they should and form a tumor.

The most common genetic change responsible for this is a fusion between two genes, KIAA1549 and BRAF. A gene fusion occurs when two genes that are normally separate are joined, creating a new gene that functions abnormally. The KIAA1549::BRAF fusion is found in about 70% of sporadic (non-inherited) pilocytic astrocytomas and is particularly common in cerebellar tumors. Less commonly, a different change in the BRAF gene, called the V600E mutation, is present, or changes occur in other MAPK pathway genes, such as FGFR1 or NTRK.

For most patients, these genetic changes occur by chance during brain development. There is no known environmental cause, and nothing the parents did or did not do caused the tumor to form.

However, a small number of pilocytic astrocytomas develop in the setting of an inherited condition. Inherited conditions are caused by a genetic change that is present in every cell of the body from birth and can be passed from parent to child. Inherited conditions associated with pilocytic astrocytoma include:

• Neurofibromatosis type 1 (NF1) — caused by a change in the NF1 gene. Between 5% and 20% of people with NF1 develop a pilocytic astrocytoma, and most of these tumors arise in the optic pathway. NF1 is also associated with other features, such as café-au-lait spots on the skin, small nodules on the iris called Lisch nodules, and benign nerve sheath tumors called neurofibromas.
• Noonan syndrome — caused by changes in genes that also act on the MAPK pathway, including PTPN11, SOS1, and others. Noonan syndrome affects growth, heart development, and facial features, and carries a slightly increased risk of pilocytic astrocytoma and other tumors.

When a pilocytic astrocytoma is diagnosed in the optic pathway, or when multiple tumors are found, an evaluation for NF1 is usually recommended. Genetic counseling helps families understand what the results mean for the patient and for relatives who may also be at risk.

How common is pilocytic astrocytoma?

Pilocytic astrocytoma is one of the most common brain tumors in children and accounts for about 15–20% of all brain tumors in children aged 0–14. The yearly incidence is approximately 1 case per 100,000 children in the United States, and the tumor is diagnosed most often between 5 and 14 years of age. It is less common in teenagers and uncommon in adults, although it can occur at any age.

How is the diagnosis made?

The diagnosis of pilocytic astrocytoma begins when brain imaging, most often magnetic resonance imaging (MRI), reveals a mass. These tumors have a distinctive appearance on MRI: they are typically well-defined, enhance brightly after contrast administration, and often contain a large fluid-filled cyst with a small solid nodule along one wall. This cyst-and-nodule pattern is especially common in cerebellar tumors. Tumors in the optic pathway or hypothalamus more often appear as solid, enhancing masses.

The diagnosis is confirmed after a tissue sample is examined under the microscope by a pathologist. In most cases, the tissue is obtained during surgery to remove the tumor. A neurosurgeon opens the skull through an operation called a craniotomy and removes as much of the tumor as can be safely taken out. When the tumor is in a location where complete removal is not safe — for example, deep within the optic pathway or brainstem — a smaller biopsy may be performed instead, or the tumor may be followed with imaging over time and treated without a tissue diagnosis.

Under the microscope, a pilocytic astrocytoma has a recognizable appearance. The tumor cells are long and thin, with hair-like extensions that give the tumor its name (“pilocytic” comes from a Latin word meaning “hair”). The tumor typically shows a biphasic pattern, with two alternating areas: densely packed regions composed of compact, elongated cells and loosely arranged regions that appear spongy or cyst-like. Two additional microscopic findings are very characteristic: Rosenthal fibers (thick, bright pink, corkscrew-shaped structures inside tumor cells, formed from abnormal protein deposits) and eosinophilic granular bodies (small, round, pink droplets clustered within the tumor). The tumor cells themselves appear mild; they rarely show the aggressive features seen in higher-grade astrocytomas, such as many dividing cells, necrosis (areas of dead tumor), or abnormal blood vessel growth. When these aggressive features are present, the pathologist re-evaluates the diagnosis to be sure the tumor is not a different, more aggressive type.

To confirm the diagnosis and distinguish pilocytic astrocytoma from other low-grade gliomas, the pathologist uses immunohistochemistry, a laboratory test that uses antibodies to detect specific proteins in the tumor cells. Pilocytic astrocytomas typically express GFAP (glial fibrillary acidic protein) and OLIG2, two proteins that confirm the tumor has arisen from glial cells.

A rare microscopic pattern, pilomyxoid astrocytoma, was historically considered a separate tumor type but is now regarded as a pattern that can occur within pilocytic astrocytoma. Pilomyxoid tumors tend to occur in younger children, more often in the hypothalamus, and may behave slightly more aggressively than classic pilocytic astrocytoma.

WHO grade

The World Health Organization (WHO) assigns tumors of the central nervous system a grade from 1 to 4 that reflects how the tumor is expected to behave. Pilocytic astrocytoma is almost always WHO grade 1, the lowest grade, meaning the tumor grows slowly, rarely spreads beyond its original location, and generally responds well to treatment, particularly surgery. Long-term survival is the rule, not the exception.

Although WHO grade 1 tumors are often described as “benign,” it is important to understand that this word has a specific meaning in CNS tumors and does not mean “harmless.” Because pilocytic astrocytomas can arise in locations where they press on vital structures — for example, near the visual pathway or brainstem — even a low-grade tumor can cause significant symptoms and may be difficult or impossible to remove completely. The tumor cells’ behavior is favorable, but the tumor’s location determines how much trouble it causes and how easily it can be treated.

In rare cases, a pilocytic astrocytoma can transform over time into a more aggressive tumor. These are now typically classified separately as high-grade astrocytoma with piloid features.

Biomarker and molecular testing

Molecular testing is an important part of the workup for pilocytic astrocytoma. The results help confirm the diagnosis, distinguish pilocytic astrocytoma from other low-grade gliomas, identify tumors that may be eligible for targeted therapy, and detect the occasional inherited condition that may have implications for the patient and their family.

KIAA1549::BRAF fusion

The KIAA1549::BRAF fusion is the most common genetic change in pilocytic astrocytoma and is especially frequent in cerebellar tumors. The fusion is usually detected using fluorescence in situ hybridization (FISH), next-generation sequencing, or a specialized RNA-based test. A positive result strongly supports the diagnosis of pilocytic astrocytoma and argues against other low-grade gliomas. The fusion is a somatic change, meaning it is present only in the tumor cells and is not inherited.

BRAF V600E mutation

The BRAF V600E mutation is a distinct change in the BRAF gene and is found in about 10% of pilocytic astrocytomas, most often in tumors outside the cerebellum. It can be detected using immunohistochemistry (with an antibody that recognizes the abnormal V600E protein) or by DNA sequencing. The V600E mutation is clinically important because it identifies tumors that may respond to targeted drugs called BRAF inhibitors (such as dabrafenib) and MEK inhibitors (such as trametinib). These drugs are used most often for tumors that cannot be completely removed by surgery, or that have come back after previous treatment.

NF1 and other MAPK pathway alterations

In tumors arising in patients with neurofibromatosis type 1 (NF1), the underlying genetic change is usually a loss-of-function mutation in the NF1 gene. These tumors are often eligible for MEK inhibitor therapy (such as selumetinib), which has become a standard option for NF1-associated pilocytic astrocytomas that require treatment. Less commonly, other MAPK pathway changes such as FGFR1 mutations or NTRK fusions are identified. These may open the door to additional targeted therapies, particularly in clinical trials.

DNA methylation profiling

DNA methylation refers to small chemical tags attached to DNA that help control which genes are turned on or off. Different tumor types have distinct methylation patterns, almost like a fingerprint. DNA methylation profiling compares a tumor’s pattern to a large reference database and is increasingly used in specialized centers to classify low-grade gliomas and to distinguish pilocytic astrocytoma from other tumors with overlapping features. Your report may include a methylation result where this testing has been performed.

Germline genetic testing

In most cases, no inherited condition is identified, and germline testing is not required. However, germline testing — a genetic test performed on blood or saliva to look for changes present throughout the body — is recommended when the tumor arises in the optic pathway, when multiple pilocytic astrocytomas are found, when features of NF1 or Noonan syndrome are present, or when there is a strong family history of related tumors. Genetic counseling is an important part of this process.

For more information about biomarkers and molecular testing across all cancer types, visit the Biomarkers and Genetic Testing section.

What is the prognosis?

The prognosis for pilocytic astrocytoma is generally excellent. Ten-year survival rates are above 90%, and for tumors that can be completely removed by surgery, long-term survival approaches 100%. Many patients are cured by surgery alone and require no additional treatment.

Prognosis depends more on the tumor’s location and the completeness of surgical removal than on any feature of the tumor cells themselves. The features most strongly associated with a worse outcome are:

• Incomplete surgical removal — tumors that cannot be completely removed because of their location (for example, deep in the hypothalamus, optic pathway, or brainstem) are more likely to grow or come back over time.
• Deep midline or brainstem location — these locations make surgery more difficult and increase the risk of long-term symptoms, even when the tumor itself is not aggressive.
• Optic pathway tumors in very young children — particularly in the setting of NF1, these tumors can cause progressive vision loss and often require treatment even when they grow slowly.
• Pilomyxoid pattern — tumors with this microscopic pattern may behave slightly more aggressively, especially in young children and when arising in midline locations.
• Diagnosis in infancy — children diagnosed before 1 year of age tend to have worse outcomes than older children, often because of tumor location and the limitations on treatment options at this age.
• Malignant transformation — very rarely, a pilocytic astrocytoma can change over time into a more aggressive tumor. This is uncommon but can occur, particularly after radiation therapy.

Even when the tumor cannot be completely removed, many patients do well for many years with careful monitoring and, when needed, additional treatment.

What happens after the diagnosis?

Pilocytic astrocytoma is managed by a team of specialists that typically includes a neurosurgeon, a pediatric neuro-oncologist (or adult neuro-oncologist for older patients), a neuropathologist, a neuroradiologist, and — for optic pathway or hypothalamic tumors — a neuro-ophthalmologist and an endocrinologist. A geneticist or genetic counselor is involved when an inherited condition is suspected.

Surgery is the main treatment and is often curative. When the entire tumor can be safely removed, no further treatment is usually needed, and follow-up consists of regular MRI scans to watch for recurrence.

When the tumor cannot be completely removed, several options are available. Small amounts of residual tumor often remain stable for years and can simply be observed with regular imaging. If the tumor grows or causes symptoms, treatment may include:

• Chemotherapy — typically a combination of carboplatin and vincristine, often used as a first-line treatment in children with tumors that cannot be removed.
• Targeted therapy — MEK inhibitors (such as selumetinib) for NF1-associated tumors, and BRAF plus MEK inhibitors (such as dabrafenib with trametinib) for tumors with the BRAF V600E mutation. These drugs have significantly changed treatment options for patients with tumors that cannot be removed and are now a standard part of the treatment landscape.
• Radiation therapy — generally avoided in children and young adults whenever possible because of long-term effects on the developing brain. When used, it is reserved for tumors that have failed other treatments.
• Additional surgery — for tumors that grow back or become symptomatic.

Long-term follow-up is essential, even for patients who have had complete surgical removal. Follow-up typically includes regular MRI of the brain, vision testing for tumors involving the optic pathway, and hormone testing for tumors near the hypothalamus or pituitary gland. For children, developmental and cognitive monitoring is also important because the tumor itself, surgery, and any additional treatments can affect learning, memory, and behavior. Support for these long-term effects — including physical therapy, occupational therapy, educational support, and mental health care — is an important part of survivorship.

Questions to ask your doctor

• Where exactly is the tumor located, and how does the location affect treatment options?
• Was the tumor completely removed during surgery, or is there residual tumor?
• What genetic changes were identified, such as a KIAA1549::BRAF fusion or a BRAF V600E mutation?
• Is DNA methylation profiling being performed, and will it change the diagnosis or treatment plan?
• Should my child or I be evaluated for an inherited condition such as NF1 or Noonan syndrome?
• Is additional treatment needed, or is observation with regular MRI the best approach?
• If treatment is needed, which option do you recommend — chemotherapy, targeted therapy, radiation, or more surgery?
• Are we candidates for MEK or BRAF inhibitors based on the molecular findings?
• How often will we need follow-up MRI scans, and for how long?
• What symptoms should we watch for that might suggest the tumor is growing or coming back?
• What are the expected long-term effects of the tumor or its treatment on vision, hormones, learning, and development?
• What support services are available for long-term follow-up and survivorship?
• Are there clinical trials that we should consider?

For more information about this site, contact us at [email protected].